Use of Erythropoietin in patients with multiple myeloma

The prevalence of tumour anaemia in patients with multiple myeloma is greater than 80%. At the time of diagnosis 20% of these patients are already anaemic. In about 70% of patients with multiple myeloma, recombinant human erythropoietin (r-HuEPO) leads to a reduction in transfusion frequency, result...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Egerer, Gerlinde (VerfasserIn) , Harter, Christoph (VerfasserIn) , Karthaus, Meinolf (VerfasserIn) , Ho, Anthony Dick (VerfasserIn) , Goldschmidt, Hartmut (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: February 2003
In: Onkologie
Year: 2003, Jahrgang: 26, Heft: 1, Pages: 80-84
ISSN:1423-0240
DOI:10.1159/000069869
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000069869
Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/69869
Volltext
Verfasserangaben:G. Egerer, C. Harter, M. Karthaus, A.D. Ho, H. Goldschmidt

MARC

LEADER 00000caa a2200000 c 4500
001 1780928416
003 DE-627
005 20220820092210.0
007 cr uuu---uuuuu
008 211210s2003 xx |||||o 00| ||eng c
024 7 |a 10.1159/000069869  |2 doi 
035 |a (DE-627)1780928416 
035 |a (DE-599)KXP1780928416 
035 |a (OCoLC)1341436028 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Egerer, Gerlinde  |e VerfasserIn  |0 (DE-588)105502168X  |0 (DE-627)792516745  |0 (DE-576)167430882  |4 aut 
245 1 0 |a Use of Erythropoietin in patients with multiple myeloma  |c G. Egerer, C. Harter, M. Karthaus, A.D. Ho, H. Goldschmidt 
264 1 |c February 2003 
300 |a 5 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 10.12.2021 
520 |a The prevalence of tumour anaemia in patients with multiple myeloma is greater than 80%. At the time of diagnosis 20% of these patients are already anaemic. In about 70% of patients with multiple myeloma, recombinant human erythropoietin (r-HuEPO) leads to a reduction in transfusion frequency, resulting in a drop in transfusion- related side-effects like infections and immune reactions, iron overload and hyperviscosity which often negatively influence the course of disease. A further reason for the use of erythropoietin is to achieve and maintain high haemoglobin levels (11-12 g/dl), which are of considerable prognostic significance in patients with multiple myeloma. Increasing Hb levels with r-HuEPO also improve the quality of life of patients, thus leading to better therapy compliance. The trade-off between high costs of an erythropoietin treatment and lower indirect costs (infusion material, personal equipment, patient transport costs, etc.) should be evaluated. Nevertheless, an exact definition of patients for whom the use of erythropoietin is beneficial is warranted. The pathogenesis of anaemia and the clinical experiences of erythropoietin in patients with multiple myeloma are discussed. 
546 |a Mit deutscher Zusammenfassung 
700 1 |a Harter, Christoph  |d 1969-  |e VerfasserIn  |0 (DE-588)133944816  |0 (DE-627)558825788  |0 (DE-576)278400159  |4 aut 
700 1 |a Karthaus, Meinolf  |e VerfasserIn  |0 (DE-588)110269357  |0 (DE-627)537491910  |0 (DE-576)289668204  |4 aut 
700 1 |a Ho, Anthony Dick  |d 1948-  |e VerfasserIn  |0 (DE-588)108692477  |0 (DE-627)504904205  |0 (DE-576)19010466X  |4 aut 
700 1 |a Goldschmidt, Hartmut  |d 1956-  |e VerfasserIn  |0 (DE-588)102258023X  |0 (DE-627)717003809  |0 (DE-576)365637386  |4 aut 
773 0 8 |i Enthalten in  |t Onkologie  |d Basel : Karger, 1978  |g 26(2003), 1, Seite 80-84  |h Online-Ressource  |w (DE-627)300595417  |w (DE-600)1483097-8  |w (DE-576)105282863  |x 1423-0240  |7 nnas  |a Use of Erythropoietin in patients with multiple myeloma 
773 1 8 |g volume:26  |g year:2003  |g number:1  |g pages:80-84  |g extent:5  |a Use of Erythropoietin in patients with multiple myeloma 
856 4 0 |u https://doi.org/10.1159/000069869  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.karger.com/Article/FullText/69869  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20211210 
993 |a Article 
994 |a 2003 
998 |g 102258023X  |a Goldschmidt, Hartmut  |m 102258023X:Goldschmidt, Hartmut  |d 910000  |d 910100  |e 910000PG102258023X  |e 910100PG102258023X  |k 0/910000/  |k 1/910000/910100/  |p 5  |y j 
998 |g 108692477  |a Ho, Anthony Dick  |m 108692477:Ho, Anthony Dick  |d 910000  |d 910100  |e 910000PH108692477  |e 910100PH108692477  |k 0/910000/  |k 1/910000/910100/  |p 4 
998 |g 133944816  |a Harter, Christoph  |m 133944816:Harter, Christoph  |d 910000  |d 910100  |e 910000PH133944816  |e 910100PH133944816  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 105502168X  |a Egerer, Gerlinde  |m 105502168X:Egerer, Gerlinde  |d 910000  |d 910100  |e 910000PE105502168X  |e 910100PE105502168X  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1780928416  |e 4018465181 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"pubHistory":["1.1978 - 36.2013"],"part":{"pages":"80-84","issue":"1","text":"26(2003), 1, Seite 80-84","year":"2003","extent":"5","volume":"26"},"note":["Gesehen am 15.12.2023"],"id":{"issn":["1423-0240"],"zdb":["1483097-8"],"eki":["300595417"]},"physDesc":[{"extent":"Online-Ressource"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["ger"],"origin":[{"dateIssuedDisp":"1978-2013","publisherPlace":"Basel","publisher":"Karger","dateIssuedKey":"1978"}],"disp":"Use of Erythropoietin in patients with multiple myelomaOnkologie","recId":"300595417","title":[{"subtitle":"international journal for cancer research and treatment","title":"Onkologie","title_sort":"Onkologie"}]}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1780928416"],"doi":["10.1159/000069869"]},"physDesc":[{"extent":"5 S."}],"note":["Gesehen am 10.12.2021"],"name":{"displayForm":["G. Egerer, C. Harter, M. Karthaus, A.D. Ho, H. Goldschmidt"]},"title":[{"title_sort":"Use of Erythropoietin in patients with multiple myeloma","title":"Use of Erythropoietin in patients with multiple myeloma"}],"recId":"1780928416","origin":[{"dateIssuedDisp":"February 2003","dateIssuedKey":"2003"}],"language":["eng"],"person":[{"family":"Egerer","display":"Egerer, Gerlinde","given":"Gerlinde","role":"aut","roleDisplay":"VerfasserIn"},{"family":"Harter","display":"Harter, Christoph","given":"Christoph","role":"aut","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Meinolf","family":"Karthaus","display":"Karthaus, Meinolf"},{"family":"Ho","display":"Ho, Anthony Dick","role":"aut","given":"Anthony Dick","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","given":"Hartmut","role":"aut","family":"Goldschmidt","display":"Goldschmidt, Hartmut"}]} 
SRT |a EGERERGERLUSEOFERYTH2003